Get the Stockscreener App
1.80
3.74%
-0.07
Pre-market:
1.76
-0.04
-2.22%
Genenta Science Spa Adr stock is traded at $1.80, with a volume of 234.30K.
It is down -3.74% in the last 24 hours and up +186.62% over the past month.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon, a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
See More
Previous Close:
$1.87
Open:
$1.9
24h Volume:
234.30K
Relative Volume:
0.17
Market Cap:
$42.46M
Revenue:
-
Net Income/Loss:
$-7.33M
P/E Ratio:
-4.8478
EPS:
-0.3713
Net Cash Flow:
$-8.02M
1W Performance:
+0.00%
1M Performance:
+186.62%
6M Performance:
+26.76%
1Y Performance:
-53.55%
1-Day Range:
$1.76
$1.90
1-Week Range:
$1.35
$1.93
52-Week Range:
$0.55
$10.00
Genenta Science Spa Adr Stock (GNTA) Company Profile
Name
Genenta Science Spa Adr
Sector
Industry
Phone
-
Address
-
Compare GNTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNTA
Genenta Science Spa Adr
|
1.80 | 42.46M | 0 | -7.33M | -8.02M | -0.3713 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genenta Science Spa Adr Stock (GNTA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Resumed | ROTH MKM | Buy |
| Jul-25-22 | Initiated | H.C. Wainwright | Buy |
| Jan-13-22 | Initiated | Maxim Group | Buy |
Genenta Science Spa Adr Stock (GNTA) Latest News
GNTA Stock Chart | GENENTA SCIENCE SPAADR (NASDAQ:GNTA) - ChartMill
Unusual volume stocks in Tuesday's session - ChartMill
Which stocks have an unusual volume on Monday? - ChartMill
Which stocks are moving on Monday? - ChartMill
Monday's session: gap up and gap down stocks - ChartMill
Wondering what's happening in today's pre-market session? - ChartMill
Genenta Science Closes All-Share Acquisition of Remaining Stake in A.T.C. - The Globe and Mail
On Friday, there are stocks with unusual volume. Let's take a look. - ChartMill
Wondering what's happening in today's after-hours session? - ChartMill
GNTA Stock Price, Quote & Chart | GENENTA SCIENCE SPAADR (NASDAQ:GNTA) - ChartMill
Genenta Science Ends Ospedale San Raffaele License to Refocus Strategy - TipRanks
Genenta Science to Close U.S. Subsidiary and Shift CFO to Consulting Role - The Globe and Mail
Genenta Science to close US subsidiary and transition CFO to consulting role - Investing.com Canada
Genenta Science to close US subsidiary and transition CFO to consulting role By Investing.com - Investing.com South Africa
Unusual VolumeStock ScreenerNews - Finviz
Genenta Science Moves Into Aerospace With Majority Investment Deal for Sòphia High Tech - The Globe and Mail
Genenta signs Definitive Agreements with Sophia High Tech - GlobeNewswire Inc.
Genenta Science Warned by Nasdaq Over Minimum Bid Price Compliance - The Globe and Mail
Genenta Science receives Nasdaq notice on minimum bid price compliance By Investing.com - Investing.com India
Genenta Science receives Nasdaq notice on minimum bid price compliance - Investing.com
What's going on in today's pre-market session - chartmill.com
Genenta Moves to Acquire Control of Italian Space-Defense Supplier Sòphia High Tech - TipRanks
Genenta Science Cancels Late-March Vote on Rebrand to Saentra Forge - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Gain Therapeutics (GANX) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business - Finviz
11 Best Italian Stocks to Buy in 2026 - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Reviva Pharmaceuticals Holdings (RVPH) and Prenetics Group (PRE) - The Globe and Mail
Genenta Science Piv A Strategic Shift from Biotech to Defense - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Genenta Science stock soars on strategic pivot to defense sector By Investing.com - Investing.com Australia
Genenta Science stock soars on strategic pivot to defense sector - Investing.com
Genenta to Rebrand as Saentra Forge and Pivot into Italian National-Security Industrial Consolidator - TipRanks
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and BioLife Solutions (BLFS) - The Globe and Mail
Genenta Science (NASDAQ:GNTA) Trading Up 0.7% – Here’s What Happened - Defense World
Operating cash flow per share of Genenta Science SpA Sponsored ADR – FWB:K5F - TradingView — Track All Markets
Genenta Science stock soars after update on glioblastoma treatment study - Investing.com
Genenta Science (NASDAQ:GNTA) Shares Down 3.4% – Should You Sell? - Defense World
Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX) - The Globe and Mail
Genenta Science Secures $15 Million in Registered Direct Offering - TipRanks
Genenta Science Appoints New Board Member and Confirms CEO - TipRanks
Genenta Science stock plunges after $15 million ADS offering - Investing.com
Genenta Science Soars Following Strategic Collaboration with Anemocyte - StocksToTrade
Genenta Science Stock Skyrockets After Strategic Collaboration Announcement - StocksToTrade
Get insights into the top gainers and losers of Friday's after-hours session. - ChartMill
Leadership Change at Genenta Science SpA: Dr. Galimi Appointed Acting CMO - The Globe and Mail
Genenta Science Spa Adr Stock (GNTA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):